New cancer drug combo tested in japan for Tough-to-Treat tumors
NCT ID NCT07176975
Summary
This is an early safety study for Japanese adults with advanced solid tumors that have spread and no longer respond to standard treatments. The main goal is to find the highest safe dose of a new drug called BI 1831169 when given alongside an existing immunotherapy (an anti-PD1 antibody). Doctors will closely monitor participants for side effects and how their tumors respond to the combination treatment for up to one year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center Hospital East
Chiba, Kashiwa, 277-8577, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.